iCell Gene Therapeutics Presents First-in-Human Data of CLL1-CD33 Compound CAR T in Refractory Acute Myeloid Leukemia
NEW YORK--(BUSINESS WIRE)--Dec 5, 2018--iCell Gene Therapeutics, LLC announced results from a study ongoing at Chengdu Military General Hospital of ICG144, the first CLL1-CD33 Compound CAR T-cell (cCAR) in clinical study, in patients with particularly difficult to treat Acute Myeloid Leukemia (AML). Patients 1 and 2 both failed multiple previous cycles of therapy and presented with complex conditions limiting further options. Treatment with CLL1-CD33 cCAR led both patients to complete response and engraftment of haploidentical stem cell transplantation (allo-HSCT) without myeloablative conditioning.
“Patient response seen to date is encouraging for refractory AML patients, and opens the potential of this novel therapy as bridge to transplant, a supplement to chemotherapy, or as a standalone therapy for patients with acute myeloid leukemia.” stated Dr. Fang Liu, MD, PhD, the Principal Investigator of the study who presented the results at the 60 th American Society of Hematology (ASH) Annual Meeting in San Diego. Dr. Yupo Ma, MD, PhD, Chairman of iCell Gene Therapeutics added, “Initial patient experience highlights the potential importance of iCell’s proprietary multiple antigen targeting and enhancing technologies to overcome antigen escape and improve treatment outcomes.”
Upon enrollment, patients receive a lymphodepletion regimen consisting of fludarabine and cyclophasphamide followed by 1x10 6 – 2x10 6 CAR T cells/kg, nonmyeloablative conditioning and Haplo-HSCTPatient 1 is a 6-year-old originally diagnosed with Franconi anemia transformed JMML and eventually to AML-M5 with more than 90% blasts in the marrow, complex karyotype and FLT3-ITD mutation. Patient 2 is a 23-year-old, failed to TKIs, AP-CML (basophils>20%, plt>1000X10 9 /L), T315I mutation. Complete response and Haplo-HSCT engraftment was observed in both patients. Grade 1 CRS and pancytopenia was observed in both patients. Grade 3 neurotoxicity was observed in Patient 1.
About CLL1-CD33 cCAR T cell therapy
CLL1-CD33 cCAR is a compound Chimeric Antigen Receptor (cCAR) immunotherapy with two distinct functional CAR molecules expressed on a T-cell, directed against the surface proteins CLL1 and CD33. The diseases treated by CLL1-CD33 cCAR could include acute myeloid leukemia, myelodysplastic syndromes, chronic myeloid leukemia and chronic myeloproliferative neoplasms. CLL1 is associated with leukemia stem cells and disease relapse, while CD33 is expressed on bulky AML disease. Treatment of AML is a challenge due to heterogeneity of AML bearing cells, which renders single antigen targeting CAR T-cell therapy ineffective. ICG144 cCAR is designed to target the mechanisms of single-CAR relapse, specifically antigen escape and leukemic stem cells.
Acute myeloid leukemia (AML) is the abnormal proliferation of immature myeloid cells and the most common leukemia in adults. Prognosis is dismal when AML relapses or is refractory to chemotherapy. Mortality associated with this disease is high, with approximately 10,000 deaths in 2018 in the US.
About iCell Gene Therapeutics
iCell Gene Therapeutics, located in Stony Brook, New York, is a clinical-stage biotechnology company developing first-in-class chimeric antigen receptor engineered cells. Clinical studies on our CARvac, T-cell targeted CARs, Compound CARs and Non-gene edited universal CARs are ongoing in the US and in China. For more information, please visit www.icellgene.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20181205005890/en/
CONTACT: Media and Investors
Tel: (917) 282-2737
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL
SOURCE: iCell Gene Therapeutics, LLC
Copyright Business Wire 2018.
PUB: 12/05/2018 07:12 PM/DISC: 12/05/2018 07:12 PM